Morvilvax0.5 ml

Morvilvax is a live attenuated viral vaccine indicated for active immunization for the prevention of measles (rubeola) infection.

Established / Guideline-Supported Use

• Routine childhood immunization against measles as part of the national immunization schedule, typically administered as a combination vaccine (e.g. measles-rubella [MR] or measles-mumps-rubella [MMR]) in most national programs, of which the measles antigen is the component described here.
• Outbreak response and supplemental immunization activities, per WHO and national health authority recommendations.
• Catch-up vaccination for children, adolescents, or adults who are unvaccinated or incompletely vaccinated and lack evidence of immunity.

Special-Situation / Post-Exposure Use

• Post-exposure prophylaxis in susceptible individuals if given within 72 hours of measles exposure (may prevent or modify disease); this is a guideline-supported but time-limited use.

Actual vaccination schedule (age at dose 1, dose 2, and any outbreak-related extra doses) should follow the prevailing national immunization program and physician guidance, as this can vary by country and epidemiologic context.

Each reconstituted dose of Measles Vaccine contains a live attenuated measles virus strain grown in cell culture, in a potency sufficient to provide protective immunity, along with stabilizers (e.g. sorbitol, hydrolyzed gelatin) and trace residual components from the manufacturing process (e.g. neomycin, egg or chick-embryo-derived proteins depending on strain/manufacturer). Exact strain, excipients, and quantitative composition vary by manufacturer/formulation; refer to the specific product's approved package insert for full quantitative composition.

Morvilvax is a live attenuated viral vaccine used to actively immunize susceptible individuals against measles, a highly contagious viral illness that can cause serious complications including pneumonia, encephalitis, and death, particularly in young children and immunocompromised persons.

Morvilvax is usually supplied as a lyophilized (freeze-dried) powder that is reconstituted with a specific diluent immediately before administration by subcutaneous (or in some formulations, intramuscular) injection. It is frequently given as part of a combination vaccine (measles-rubella or measles-mumps-rubella) rather than as a single-antigen product, in line with most national immunization programs.

Morvilvax belongs to the therapeutic class of live attenuated viral vaccines, specifically the measles-containing vaccine group used for active immunoprophylaxis.

Mechanism

Measles Vaccine contains a live, attenuated (weakened) strain of measles virus that, after administration, undergoes limited replication in the vaccinated individual without causing clinical measles disease in the vast majority of recipients. This subclinical replication stimulates both humoral (neutralizing antibody) and cell-mediated immune responses directed against the measles virus.

Immune Response

Seroconversion (development of protective antibody) occurs in approximately 85-95% of recipients after a single dose given at 9-12 months of age, and in more than 95-97% after a second dose or when the first dose is given at 12 months of age or later. Protection is generally considered long-lasting, often lifelong, after the complete recommended dosing schedule.

Morvilvax is administered by subcutaneous injection (or intramuscular, depending on formulation/manufacturer) after reconstitution with the supplied diluent. It should be given using a sterile needle and syringe, using a separate site and separate syringe if co-administered with other injectable vaccines. Do not administer intravenously. Only reconstituted vaccine that has not exceeded the manufacturer's stated use time should be administered; discard any unused reconstituted vaccine after that time.

Immunoglobulin / Blood Products

Recent receipt of antibody-containing blood products (whole blood, plasma, immunoglobulin) can neutralize the live virus in Morvilvax and reduce its effectiveness. Vaccination should generally be deferred for an interval after such products (commonly 3-11 months depending on product and dose), and if the vaccine is given first, immunoglobulin should generally be avoided for at least 2 weeks afterward unless it is essential. Follow current national/WHO guidance for the specific product and interval.

Immunosuppressive Therapy

Concurrent immunosuppressive therapy (high-dose corticosteroids, chemotherapy, biologic immunosuppressants, radiation) can blunt the immune response to Morvilvax and, because it is a live vaccine, may increase the risk of disseminated infection from the vaccine strain; see Contraindications and Precautions.

Other Live Vaccines

Other live attenuated vaccines can generally be co-administered with Morvilvax at the same visit; if not given simultaneously, they should generally be separated by at least 4 weeks.

Tuberculin Skin Testing

Morvilvax may transiently suppress tuberculin skin test reactivity; testing should be done either on the same day as vaccination or deferred for about 4-6 weeks afterward.

Most reactions to Morvilvax are mild and self-limited.

Common

• Injection-site pain, redness, or swelling
• Mild fever, typically occurring 5-12 days after vaccination
• Transient measles-like rash, typically occurring 5-12 days after vaccination
• Irritability, malaise

Less Common

• Febrile seizure (usually related to the post-vaccination fever)
• Transient joint pain/swelling (more relevant to the rubella component in combination vaccines)
• Mild, transient thrombocytopenia

Rare

• Anaphylaxis or other severe allergic reaction
• Encephalitis or encephalopathy (very rare)

Pregnancy

Morvilvax is a live attenuated vaccine and is contraindicated in pregnancy because of a theoretical risk to the fetus. Women should avoid becoming pregnant for at least 4 weeks (one month) after receiving Morvilvax. If a dose is inadvertently given during pregnancy, this is not generally considered a reason to terminate the pregnancy, but the patient should inform her physician. Use only if clearly needed and only after consulting a physician, and in general it should not be given during pregnancy.

Lactation

Morvilvax is generally considered compatible with breastfeeding; live Morvilvax virus is not known to be transmitted to the infant through breast milk in a way that causes harm. Breastfeeding mothers who need vaccination should consult a physician for individualized guidance.

• Acute illness: Defer administration of Morvilvax in individuals with moderate or severe acute febrile illness until recovery; minor illnesses (e.g. mild upper respiratory infection) without fever are not a reason to delay.
• Thrombocytopenia: Rare cases of thrombocytopenia have been reported after measles-containing vaccines; use caution in individuals with a history of thrombocytopenia or thrombocytopenic purpura, as a subsequent dose could theoretically provoke recurrence.
• Expected post-vaccination fever/rash: Fever and a mild, transient rash commonly occur 5-12 days after vaccination and are expected, self-limiting reactions rather than signs of allergy or infection.
• History of febrile seizures: Use with appropriate counseling and fever-monitoring advice in children with a personal or family history of seizures.
• Altered immunity: Use caution and individualized specialist assessment in persons with HIV infection who are not severely immunocompromised, as Morvilvax may still be recommended for this group per current guidance; severely immunocompromised individuals should not receive it (see Contraindications).
• Anaphylaxis preparedness: As with any injectable vaccine, epinephrine and appropriate medical support should be available at the time of administration in case of an acute allergic reaction.

There is no established scenario of clinically meaningful "overdose" with Morvilvax, as it is given as single discrete doses rather than a titrated medication. If an excessive volume/dose or an extra dose is inadvertently administered, or if a severe reaction occurs, seek immediate medical attention or contact emergency services/a poison control center for evaluation and supportive care rather than attempting home management.

Store the lyophilized vaccine refrigerated at 2°C to 8°C (36°F to 46°F), protected from light, and do not freeze the diluent. Follow the manufacturer's specific storage instructions, as some formulations may require freezer storage before reconstitution. Once reconstituted, use within the manufacturer's specified time window and discard any unused portion. Keep out of reach of children.

Pregnancy

Contraindicated; see Pregnancy and Lactation.

Immunocompromised Individuals

Contraindicated in severe immunosuppression; see Contraindications. Individualized specialist guidance is needed for persons with HIV infection or other altered immune states who are not severely immunocompromised.

Elderly

Morvilvax is not typically indicated for routine use in the elderly, but may be given to older adults without evidence of measles immunity (e.g. before international travel), following the same dosing as adults.

Renal/Hepatic Impairment

No dose adjustment is established or generally required for renal or hepatic impairment, as Morvilvax is not systemically metabolized or renally cleared in the manner of conventional drugs.

Morvilvax is not a continuous treatment but is given as one or two discrete doses (per the national immunization schedule) to establish long-term, generally lifelong, immunity. No ongoing or repeated dosing beyond the recommended primary schedule is required unless specifically advised by a physician or public health authority (for example, during an outbreak or for certain occupational/travel indications).

Morvilvax is supplied as a lyophilized powder that must be reconstituted with the diluent supplied by the manufacturer (do not substitute a different diluent). Withdraw the full volume of diluent and inject it into the vial of lyophilized vaccine; gently swirl (do not shake vigorously) until completely dissolved. Inspect visually for particulate matter or discoloration before use. Use the reconstituted vaccine promptly, within the manufacturer's stated time limit (commonly within 30 minutes to 8 hours, kept refrigerated and protected from light), and discard any unused reconstituted vaccine after that time.

Measles Vaccine is classified as a live attenuated viral vaccine, within the broader category of active immunizing biological products.

Measles Vaccine works by introducing a live, attenuated strain of measles virus that replicates minimally in the host, stimulating an active immune response (neutralizing antibodies and cell-mediated immunity) without producing clinical measles disease in the great majority of recipients. This primes the immune system to recognize and rapidly respond to wild-type measles virus on future exposure, preventing or substantially reducing the severity of infection.

Morvilvax is a cornerstone of pediatric immunization and is indicated for infants and children per the national immunization schedule, typically starting at 9-12 months of age (the first dose may be given earlier, e.g. from 6 months, in outbreak or high-risk settings per public health guidance, but doses given before 12 months are often followed by additional routinely scheduled doses because of potentially reduced seroconversion in the presence of residual maternal antibody). Safety and efficacy in infants younger than the minimum age recommended by the national program have not been established outside of specific outbreak-control guidance. Fever and transient rash 5-12 days post-vaccination are expected and self-limiting in children.